Logo image of 1LLY.MI

ELI LILLY & CO (1LLY.MI) Stock Fundamental Analysis

BIT:1LLY - Euronext Milan - US5324571083 - Common Stock - Currency: EUR

666.7  -1.9 (-0.28%)

Fundamental Rating

6

Overall 1LLY gets a fundamental rating of 6 out of 10. We evaluated 1LLY against 51 industry peers in the Pharmaceuticals industry. 1LLY has an excellent profitability rating, but there are some minor concerns on its financial health. 1LLY is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

1LLY had positive earnings in the past year.
In the past year 1LLY had a positive cash flow from operations.
1LLY had positive earnings in each of the past 5 years.
In the past 5 years 1LLY always reported a positive cash flow from operatings.
1LLY.MI Yearly Net Income VS EBIT VS OCF VS FCF1LLY.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

1.2 Ratios

1LLY has a Return On Assets of 12.42%. This is amongst the best in the industry. 1LLY outperforms 80.39% of its industry peers.
The Return On Equity of 1LLY (70.45%) is better than 96.08% of its industry peers.
The Return On Invested Capital of 1LLY (27.17%) is better than 94.12% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1LLY is significantly above the industry average of 15.19%.
The last Return On Invested Capital (27.17%) for 1LLY is above the 3 year average (21.71%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROIC 27.17%
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
1LLY.MI Yearly ROA, ROE, ROIC1LLY.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

With an excellent Profit Margin value of 22.66%, 1LLY belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
1LLY's Profit Margin has declined in the last couple of years.
The Operating Margin of 1LLY (40.25%) is better than 94.12% of its industry peers.
1LLY's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 81.70%, 1LLY belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
1LLY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
1LLY.MI Yearly Profit, Operating, Gross Margins1LLY.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1LLY is creating value.
1LLY has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 1LLY has less shares outstanding
The debt/assets ratio for 1LLY is higher compared to a year ago.
1LLY.MI Yearly Shares Outstanding1LLY.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
1LLY.MI Yearly Total Debt VS Total Assets1LLY.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.2 Solvency

An Altman-Z score of 7.45 indicates that 1LLY is not in any danger for bankruptcy at the moment.
1LLY has a better Altman-Z score (7.45) than 96.08% of its industry peers.
A Debt/Equity ratio of 2.19 is on the high side and indicates that 1LLY has dependencies on debt financing.
1LLY's Debt to Equity ratio of 2.19 is on the low side compared to the rest of the industry. 1LLY is outperformed by 76.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Altman-Z 7.45
ROIC/WACC2.8
WACC9.7%
1LLY.MI Yearly LT Debt VS Equity VS FCF1LLY.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B 20B

2.3 Liquidity

1LLY has a Current Ratio of 1.37. This is a normal value and indicates that 1LLY is financially healthy and should not expect problems in meeting its short term obligations.
1LLY has a Current ratio (1.37) which is comparable to the rest of the industry.
A Quick Ratio of 1.06 indicates that 1LLY should not have too much problems paying its short term obligations.
1LLY has a Quick ratio of 1.06. This is in the better half of the industry: 1LLY outperforms 60.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.06
1LLY.MI Yearly Current Assets VS Current Liabilites1LLY.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 89.01% over the past year.
1LLY shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.57% yearly.
The Revenue has grown by 36.38% in the past year. This is a very strong growth!
Measured over the past years, 1LLY shows a quite strong growth in Revenue. The Revenue has been growing by 15.08% on average per year.
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%

3.2 Future

Based on estimates for the next years, 1LLY will show a very strong growth in Earnings Per Share. The EPS will grow by 30.37% on average per year.
1LLY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.76% yearly.
EPS Next Y68%
EPS Next 2Y51.7%
EPS Next 3Y42.22%
EPS Next 5Y30.37%
Revenue Next Year31.67%
Revenue Next 2Y25.5%
Revenue Next 3Y22.67%
Revenue Next 5Y17.76%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
1LLY.MI Yearly Revenue VS Estimates1LLY.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
1LLY.MI Yearly EPS VS Estimates1LLY.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 54.47, the valuation of 1LLY can be described as expensive.
66.67% of the companies in the same industry are cheaper than 1LLY, based on the Price/Earnings ratio.
1LLY's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.60.
The Price/Forward Earnings ratio is 25.05, which means the current valuation is very expensive for 1LLY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1LLY indicates a slightly more expensive valuation: 1LLY is more expensive than 60.78% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of 1LLY to the average of the S&P500 Index (22.43), we can say 1LLY is valued inline with the index average.
Industry RankSector Rank
PE 54.47
Fwd PE 25.05
1LLY.MI Price Earnings VS Forward Price Earnings1LLY.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1LLY is valued a bit more expensive than the industry average as 66.67% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 34.6
1LLY.MI Per share data1LLY.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1LLY has an outstanding profitability rating, which may justify a higher PE ratio.
1LLY's earnings are expected to grow with 42.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.8
PEG (5Y)3.29
EPS Next 2Y51.7%
EPS Next 3Y42.22%

More info and screens

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.82%, 1LLY is not a good candidate for dividend investing.
In the last 3 months the price of 1LLY has falen by -20.16%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
Compared to an average industry Dividend Yield of 3.09, 1LLY has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.36, 1LLY's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.82%

5.2 History

The dividend of 1LLY is nicely growing with an annual growth rate of 15.60%!
Dividend Growth(5Y)15.6%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

1LLY pays out 43.74% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of 1LLY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP43.74%
EPS Next 2Y51.7%
EPS Next 3Y42.22%
1LLY.MI Yearly Income VS Free CF VS Dividend1LLY.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B 6B 8B 10B
1LLY.MI Dividend Payout.1LLY.MI Dividend Payout, showing the Payout Ratio.1LLY.MI Dividend Payout.PayoutRetained Earnings

More info and screens

ELI LILLY & CO

BIT:1LLY (5/20/2025, 7:00:00 PM)

666.7

-1.9 (-0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners83.27%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap632.02B
Analysts81.21
Price Target893.78 (34.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.82%
Yearly Dividend4.41
Dividend Growth(5Y)15.6%
DP43.74%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.92%
Min EPS beat(2)6.45%
Max EPS beat(2)9.38%
EPS beat(4)3
Avg EPS beat(4)11.23%
Min EPS beat(4)-20.34%
Max EPS beat(4)49.43%
EPS beat(8)7
Avg EPS beat(8)29.89%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)11
Avg EPS beat(16)14.81%
Revenue beat(2)0
Avg Revenue beat(2)-0.87%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.5%
Revenue beat(4)1
Avg Revenue beat(4)1.15%
Min Revenue beat(4)-6.46%
Max Revenue beat(4)12.82%
Revenue beat(8)4
Avg Revenue beat(8)2.39%
Revenue beat(12)5
Avg Revenue beat(12)0.98%
Revenue beat(16)9
Avg Revenue beat(16)1.3%
PT rev (1m)-5.41%
PT rev (3m)-5.44%
EPS NQ rev (1m)0.18%
EPS NQ rev (3m)0.71%
EPS NY rev (1m)-5.77%
EPS NY rev (3m)-6.13%
Revenue NQ rev (1m)0.4%
Revenue NQ rev (3m)0.6%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)0.29%
Valuation
Industry RankSector Rank
PE 54.47
Fwd PE 25.05
P/S 14.5
P/FCF N/A
P/OCF 76.25
P/B 45.07
P/tB 178.41
EV/EBITDA 34.6
EPS(TTM)12.24
EY1.84%
EPS(NY)26.62
Fwd EY3.99%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)8.74
OCFY1.31%
SpS45.98
BVpS14.79
TBVpS3.74
PEG (NY)0.8
PEG (5Y)3.29
Profitability
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROCE 33.25%
ROIC 27.17%
ROICexc 28.73%
ROICexgc 36.37%
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
FCFM N/A
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
ROICexc(3y)23.23%
ROICexc(5y)21.74%
ROICexgc(3y)32.89%
ROICexgc(5y)32.31%
ROCE(3y)29.19%
ROCE(5y)26%
ROICexcg growth 3Y1.59%
ROICexcg growth 5Y4.02%
ROICexc growth 3Y9.55%
ROICexc growth 5Y8.81%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 578.92%
Cap/Sales 21.61%
Interest Coverage 250
Cash Conversion 43.23%
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.06
Altman-Z 7.45
F-Score6
WACC9.7%
ROIC/WACC2.8
Cap/Depr(3y)374.28%
Cap/Depr(5y)279.43%
Cap/Sales(3y)16.34%
Cap/Sales(5y)12.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
EPS Next Y68%
EPS Next 2Y51.7%
EPS Next 3Y42.22%
EPS Next 5Y30.37%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%
Revenue Next Year31.67%
Revenue Next 2Y25.5%
Revenue Next 3Y22.67%
Revenue Next 5Y17.76%
EBIT growth 1Y73.83%
EBIT growth 3Y31.18%
EBIT growth 5Y24.1%
EBIT Next Year96.28%
EBIT Next 3Y44.1%
EBIT Next 5Y29.16%
FCF growth 1Y-133.54%
FCF growth 3Y-57.48%
FCF growth 5Y-34.68%
OCF growth 1Y36.68%
OCF growth 3Y6.69%
OCF growth 5Y12.76%